Modern immunosuppression

Clinics in Liver Disease

Volumn 4, Issue 3, 2000, Pages 619-655

  Cronin II, David C ^a   Faust, Thomas W ^b   Brady, Lynda ^c   Conjeevaram, Hari ^b   Jain, Sushil ^b   Gupta, Puneet ^c   Millis, J Michael ^a  

^a Department of Surgery   (United States)

^b Liver Study Unit

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

DRUG INDUCED DISEASE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; REVIEW; STEROID THERAPY;

EID: 0033885462     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70130-6     Document Type: Article

References (220)

1. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation: The U.S. Multicenter FK506 Liver Study Group [see comments] N Engl J Med 331 1994 1110
2. M.S. Abouljoud M.F. Levy G.B. Klintmalm Hyperlipidemia after liver transplantation: Long-term results of the FK506/cyclosporine a US multicenter trial Transplant Proc 27 1995 1121
3. D. Abramowicz L. De Pauw A. Le Moine Prevention of OKT3 nephrotoxicity after kidney transplantation Kidney Int 53 suppl 1996 S39
4. A.C. Allison E.M. Eugui Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil Immunol Rev 136 1993 5
5. A.C. Allison W.J. Kowalski C.D. Muller Mechanisms of action of mycophenolic acid Ann NY Acad Sci 696 1993 63
6. T.F. Andoh E.A. Burdmann J. Lindsley Functional and structural characteristics of experimental FK 506 nephrotoxicity Clin Exp Pharmacol Physiol 22 1995 646
7. E. Atillasoy A. Gurkan E. Mor Cholesterol levels long term after liver transplant Transplant Proc 30 1998 2049
8. V. Balan K. Abu-Elmagd A.J. Demetris Autoimmune liver diseases: recurrence after liver transplantation Surg Clin North Am 79 1999 147
9. J.L. Berard R.L. Velez R.B. Freeman A review of interleukin-2 receptor antagonists in solid organ transplantation Pharmacotherapy 19 1999 1127
10. B.E. Bierer P.S. Mattila R.F. Standaert Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin Proc Natl Acad Sci U S A 87 1990 9231
11. A.H. Birnbaum K.J. Benkov N.S. Pittman Recurrence of autoimmune hepatitis in children after liver transplantation J Pediat Gastroenterol Nutr 25 1997 20
12. N. Bonnefoy-Berard M. Flacher J.P. Revillard Antiproliferative effect of antilymphocyte globulins on B cells and B- cell lines Blood 79 1992 2164
13. N. Bonnefoy-Berard J.P. Revillard Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3 J Heart Lung Transplant 15 1996 435
14. N. Bonnefoy-Berard B. Verrier C. Vincent Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins Immunology 77 1992 61
15. D.C. Brennan K. Flavin J.A. Lowell A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [published erratum appears in Transplantation 1999 May 27;67:1386] Transplantation 67 1999 1011
16. S. Buysmann F.J. Bemelman P.T. Schellekens Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3 Blood 87 1996 404
17. T.V. Cacciarelli M. Green R. Jaffe Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy Transplantation 66 1998 1047
18. R.Y. Calne K. Rolles D.J. White Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers Lancet 2 1979 1033
19. V.J. Canzanello L. Schwartz S.J. Taler Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506) Liver Transpl Surg 3 1997 1
20. V.J. Canzanello S.C. Textor S.J. Taler Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK506) Liver Transplant Surg 4 1998 328
21. V.J. Canzanello S.C. Textor S.J. Taler Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation J Am Soc Nephrol 5 1995 1910
22. P.M. Capone M.E. Cohen Seizures and cerebritis associated with administration of OKT3 Pediatr Neurol 7 1991 299
23. A.M. Castelao J.M. Grino E. Andres HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation Transplant Proc 25 1993 1043
24. C.K. Chan G.A. Head Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine J Hypertens 14 1996 855
25. R. Charco C. Cantarell V. Vargas Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy Liver Transplant Surg 5 1999 204
26. U. Christians K.F. Sewing Cyclosporin metabolism in transplant patients Pharmacol Ther 57 1993 291
27. J. Chung C.J. Kuo G.R. Crabtree Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases Cell 69 1992 1227
28. G. Ciancio A.P. Siquijor G.W. Burke Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era Clin Transplant 11 1997 243
29. J.O. Colonna L.I. Goldstein J.J. Brems A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection Arch Surg 122 1987 1120
30. D.K. Cooper D. Novitzky L. Davis Does central nervous system toxicity occur in transplant patients with hypercholesterolemia receiving cyclosporine? J Heart Transplant 8 1989 221
31. A.B. Cosimi S.I. Cho F.L. Delmonico A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection Transplant Proc 19 1 Pt 3 1987 2431
32. M.R. Costanzo-Nordin Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction Transplant Proc 25 1993 21
33. D. D'Agostino M. Gimenez B. Yamaguchi Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients Transplantation 62 1996 1068
34. L. De Carlis L.S. Belli G.F. Rondinara Early steroid withdrawal in liver transplant patients: final report of a prospective randomized trial Transplant Proc 29 1997 539
35. P. deGroen Cyclosporine, low density lipoprotein, and cholesterol Mayo Clinic Proc 63 1988 1012
36. J. Devlin D. Doherty L. Thomson Defining the outcome of immunosuppression withdrawal after liver transplantation Hepatology 27 1998 926
37. J. Devlin R. Williams Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants Transplantation 62 1996 1251
38. O. Dietze W. Vogel R. Margreiter Primary biliary cirrhosis (PBC) after liver transplantation Transplant Proc 22 1990 1501
39. J. Dmitrewski S.G. Hubscher A.D. Mayer Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression J Hepatol 24 1996 253
40. H.R. Doyle F. Morelli J. McMichael Hepatic retransplantation: an analysis of risk factors associated with outcome Transplantation 61 1996 1499
41. C.B. Drachenberg D.K. Klassen M.R. Weir Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation Transplantation 68 1999 396
42. F.J. Dumont M.J. Staruch S.L. Koprak Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin J Immunol 144 1990 251
43. S.P. Dunn G.F. Cooney A. Kulinsky Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients Transplantation 60 1995 1438
44. S.P. Dunn K. Falkenstein J.P. Lawrence Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients Transplantation 57 1994 544
45. D.E. Eckhoff B.M. McGuire L.R. Frenette Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation Transplantation 65 1998 180
46. H. Ekberg L. Backman G. Tufveson Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups Transplant Proc 31 1999 267
47. E.T. Elwood C.P. Larsen D.H. Maurer Microchimerism and rejection in clinical transplantation [see comments] Lancet 349 1997 1358
48. C.O. Esquivel J.J. Fung B. Markus OKT3 in the reversal of acute hepatic allograft rejection Transplant Proc 19 1 Pt 3 1987 2443
49. G.M. Ferron E.V. Mishina J.J. Zimmerman Population pharmacokinetics of sirolimus in kidney transplant patients Clin Pharmacol Ther 61 1997 416
50. N.C. Fisher P.G. Nightingale B.K. Gunson Chronic renal failure following liver transplantation Transplantation 66 1998 59
51. R.A. Fisher J.M. Ham A. Marcos A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation Transplantation 66 1998 1616
52. D. Freeman D. Grant G. Levy Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients Ther Drug Monit 17 1995 213
53. J.P. Fryer M.V. Fortier P. Metrakos Central pontine myelinolysis and cyclosporine neurotoxicity following liver transplantation Transplantation 61 1996 658
54. J. Fung K. Abu-Elmagd A. Jain A randomised trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine Transplant Proc 23 1991 2977 2983
55. J.J. Fung S. Todo A. Jain Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications Transplant Proc 22 1990 6
56. J.J. Fung S. Todo A. Tzakis Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls Transplant Proc 23 1 Pt 1 1991 14
57. A.O. Gaber M.R. First R.J. Tesi Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation Transplantation 66 1998 29
58. R. Gomez E. Moreno F. Colina Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients J Hepatol 28 1998 150
59. R.D. Gordon A.G. Tzakis S. Iwatsuki Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation Am J Kidney Dis 11 1988 141
60. J.A. Goss C.R. Shackleton D.G. Farmer Orthotopic liver transplantation for primary sclerosing cholangitis: A 12-year single center experience Ann Surg 225 1997 472
61. S.F. Gothel M.A. Marahiel Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts Cell Mol Life Sci 55 1999 423
62. D. Grant J. Rochon G. Levy Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group Transplant Proc 28 1996 2232
63. M. Green T.V. Cacciarelli G.V. Mazariegos Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease Transplantation 66 1998 1641
64. C.G. Groth L. Backman J.M. Morales Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group [see comments] Transplantation 67 1999 1036
65. SR Group. Studies of Pediatric Liver Transplantation (SPLIT) Annual Report: EMMES, 1999.
66. O. Guckelberg J.M. Langrehr W.O. Bechstein Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? Transplant Proc 28 1996 3173
67. P. Hauters B. de Hemptinne M. Carlier Long-term analysis of glomerular filtration rate and hypertension in adult liver transplant recipients treated with cyclosporine A Transplant Proc 23 1991 1458
68. M. Hayashi E.B. Keeffe S.M. Krams Allograft rejection after liver transplantation for autoimmune liver diseases Liver Transplant Surg 4 1998 208
69. M.F. Hebert N.L. Ascher J.R. Lake Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients Transplantation 67 1999 707
70. J.I. Herrero J. Quiroga B. Sangro Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil Liver Transplant Surg 5 1999 414
71. Y. Hirano S. Fujihira K. Ohara Morphological and functional changes of islets of Langerhans in FK506- treated rats Transplantation 53 1992 889
72. M. Ho R. Jaffe G. Miller The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children Transplantation 45 1988 719
73. S. Ho N. Clipstone L. Timmermann The mechanism of action of cyclosporin A and FK506 Clin Immunol Immunopathol 80 3 Pt 2 1996 S40
74. S.G. Hubscher E. Elias J.A.C. Buckels Primary biliary cirrhosis: histological evidence of disease recurrence after liver transplantation J Hepatol 18 1993 173
75. D.K. Imagawa S. Dawson C.D. Holt Hyperlipidemia after liver transplantation Transplantation 62 1996 934
76. A. Jain D. Brody I. Hamad Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus [in process citation] Transplantation 69 2000 172
77. A. Jain J. Reyes R. Kashyap Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients Transplant Proc 30 1998 1403
78. A. Jain J. Reyes R. Kashyap What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients Ann Surg 230 1999 441
79. D.R. Jeyarajah G.J. Netto S.P. Lee Recurrent primary sclerosing cholangitis after orthotopic liver transplantation Transplantation 66 1998 1300
80. R.M. Jindal I. Popescu S. Emre Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506 Transplantation 57 1994 1395
81. M.R. Johnson G.M. Mullen E.J. O'Sullivan Risk/benefit ratio of perioperative OKT3 in cardiac transplantation Am J Cardiol 74 1994 261
82. S. Jonas W.O. Bechstein S.G. Tullius Indications for tacrolimus anti-rejection therapy in liver allograft recipients Transpl Int 1 9 Suppl 1996 S164
83. B.D. Kahan B.A. Julian M.D. Pescovitz Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group Transplantation 68 1999 1526
84. B.D. Kahan J. Podbielski K.L. Napoli Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation Transplantation 66 1998 1040
85. B.D. Kahan P.R. Rajagopalan M. Hall Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti- interleukin-2-receptor monoclonal antibody. United Stated Simulect Renal Study Group Transplantation 67 1999 276
86. B.D. Kahan R.L. Wong C. Carter A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients Transplantation 68 1999 1100
87. T. Kato P. Ruiz W. DeFaria Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection Transplant Proc 31 1999 396
88. P.A. Keown Molecular and clinical therapeutics of cyclosporine in transplantation L.C. Ginns A.B. Cosimi P.J. Morris Transplantation 1999 Blackwell Science Malden, MA 101
89. G.B. Klintmalm R. Goldstein T. Gonwa Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group Transplant Proc 25 1 Pt 1 1993 641
90. G.B. Klintmalm R. Goldstein T. Gonwa Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group Transplant Proc 25 1 Pt 1 1993 679
91. J. Klupp M. Glanemann W.O. Bechstein Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation Transplant Proc 31 1-2 1999 1113
92. J. Kovarik T. Breidenbach C. Gerbeau Disposition and immunodynamics of basiliximab in liver allograft recipients Clin Pharmacol Ther 64 1998 66
93. J.M. Kovarik E. Rawlings P. Sweny Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients Transpl Int 1 9 Suppl 1996 S32
94. N. Kumar W.J. Wall D.R. Grant Liver retransplantation Transplant Proc 31 1999 541
95. C.J. Kuo J. Chung D.F. Fiorentino Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase Nature 358 6381 1992 70
96. A. Lampen U. Christians A.K. Gonschior Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber Br J Pharmacol 117 1996 1730
97. A. Lampen U. Christians F.P. Guengerich Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability Drug Metab Dispos 23 1995 1315
98. C.W. Lee J.L. Logan C.F. Zukoski Cardiovascular collapse following orthoclone OKT3 administration: a case report Am J Kidney Dis 17 1991 73
99. Y.M. Lee M.M. Kaplan Primary biliary cirrhosis L.S. Friedman E.B. Keefe Handbook of Liver Disease 1998 Churchill Livingstone Edinburgh 197
100. J.C. Lin M.C. Smith J.S. Pagano Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus J Virol 50 1984 50
101. J. Liu FK506 and cyclosporin, molecular probes for studying intracellular signal transduction [published erratum appears in Immunol Today 14:399, Aug 1993] Immunol Today 14 1993 290
102. G.E. Loss Jr L. Brady H.P. Grewal Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients Transplant Proc 30 1998 1435
103. M. Loss M. Winkler A. Schneider Influence of long-term cyclosporine or FK506 therapy on glucose and lipid metabolism in stable liver graft recipients Transplant Proc 27 1995 1136
104. H. Luo H. Chen P. Daloze Inhibition of in vitro immunoglobulin production by rapamycin Transplantation 53 1992 1071
105. J.F. Markmann J. Gornbein J.S. Markowitz A simple model to estimate survival after retransplantation of the liver Transplantation 67 1999 422
106. P.S. Mattila K.S. Ullman S. Fiering The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes E mbo J 9 1990 4425
107. G.V. Mazariegos J. Reyes I.R. Marino Weaning of immunosuppression in liver transplant recipients Transplantation 63 1997 243
108. V. McAlister Z. Gao K. Pltekian Sirolimus-tacrolimus combination immunosuppression Lancet 9201 2000 355
109. S.V. McDiarmid J.O. Colonna A. Shaked A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation Transplantation 56 1993 847
110. S.V. McDiarmid J.O. Colonna II A. Shaked Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients Transplantation 55 1993 1328
111. S.V. McDiarmid D.A. Farmer L.I. Goldstein A randomized prospective trial of steroid withdrawal after liver transplantation Transplantation 60 1995 1443
112. S.V. McDiarmid S. Jordan G.S. Lee Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients Transplantation 66 1998 1604
113. S.V. McDiarmid G.B. Klintmalm R.W. Busuttil FK506 conversion for intractable rejection of the liver allograft Transpl Int 6 1993 305
114. S.V. McDiarmid M.J. Millis P.I. Terasaki OKT3 prophylaxis in liver transplantation Dig Dis Sci 36 1991 1418
115. M. McKee P. Mattei K. Schwarz Steroid withdrawal in tacrolimus (FK506)-treated pediatric liver transplant recipients J Pediatr Surg 32 1997 973
116. C. Mignat Clinically significant drug interactions with new immunosuppressive agents Drug Saf 16 1997 267
117. P. Milkiewicz S.G. Hubscher G. Skiba Recurrence of autoimmune hepatitis after liver transplantation Transplantation 68 1999 253
118. J.M. Millis D.S. Bruce K.A. Newell Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients Transplant Proc 28 1996 1014
119. J.M. Millis D.C. Cronin K.A. Newell Successful use of tacrolimus for initial rejection episodes after liver transplantation Transplant Proc 30 1998 1407
120. J.M. Millis D.C. Cronin K.A. Newell Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy Transplant Proc 29 1997 1549
121. J.M. Millis S.V. McDiarmid J.R. Hiatt Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation Transplantation 47 1989 82
122. J.M. Millis E.S. Woodle J.B. Piper Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection Transplantation 61 1996 1365
123. D.F. Mirza B.K. Gunson Z. Soonawalla Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression [letter] Lancet 349 1997 701
124. J.P. Molleston Y.G. Alevy K.S. SivaSai Evidence that pediatric liver transplant recipients may undergo late rejection episodes in spite of donor-specific microchimerism Transplantation 61 1996 656
125. G. Morgan R.A. Superina Lymphoproliferative disease after pediatric liver transplantation J Pediatr Surg 29 1994 1192
126. W.G. Morice G.J. Brunn G. Wiederrecht Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes J Biol Chem 268 1993 3734
127. W.G. Morice G. Wiederrecht G.J. Brunn Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes J Biol Chem 268 1993 22737
128. A.R. Mueller K.P. Platz W.O. Bechstein Neurotoxicity after orthotopic liver transplantation: A comparison between cyclosporine and FK506 Transplantation 58 1994 155
129. E.A. Mueller J.M. Kovarik J.B. van Bree Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation Pharm Res 11 1994 301
130. L.L. Mulloy F. Wright M.L. Hall Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors Transplant Proc 31 1999 1210
131. S. Narumi J.P. Roberts J.C. Emond Liver transplantation for sclerosing cholangitis Hepatology 22 1995 451
132. B. Nashan R. Moore P. Amlot Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group [published erratum appears in Lancet 1997 Nov 15;350(9089):1484] Lancet 350 9086 1997 1193
133. J. Neuberger B. Portman R. Calne Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting Transplantation 37 1984 363
134. J. Neuberger B. Portmann B.R.D. Macdougall Recurrence of primary biliary cirrhosis after liver transplantation N Engl J Med 306 1982 1
135. P. Neuhaus W.O. Bechstein G. Blumhardt Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody Transplantation 55 1993 1320
136. P. Neuhaus G. Blumhardt W.O. Bechstein Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation Transplantation 59 1995 31
137. New monoclonal antibodies to prevent transplant rejection Med Lett Drugs Ther 40 1998 93
138. K.A. Newell E.M. Alonso P.F. Whitington Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression Transplantation 62 1996 370
139. M.A. O'Gorman B. Fivush B. Wise Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients Clin Transplant 9 1995 312
140. J.G. O'Grady A. Forbes K. Rolles An analysis of cyclosporin efficacy and toxicity after liver transplantation Transplantation 45 1988 575
141. S.V. Onrust L.R. Wiseman Basiliximab Drugs 57 1999 207
142. M.G. Otto A.D. Mayer P.A. Clavien Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral [published erratum appears in Transplantation 67:1386, 1999 May 27] Transplantation 66 1998 1632
143. R.T.A. Padbury B.K. Gunson B. Dousset Steroid withdrawal from long-term immunosuppression in liver allograft recipients Transplantation 55 1993 789
144. G.V. Papatheodoridis J. O'Beirne P. Mistry Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: A preliminary report Transplantation 68 1999 155
145. K.J. Parlevliet F.J. Bemelman S.L. Yong Toxicity of OKT3 increases with dosage: A controlled study in renal transplant recipients Transpl Int 8 1995 141
146. R. Pichlmayr M. Winkler P. Neuhaus Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study Transplant Proc 29 1997 2499
147. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection: European Mycophenolate Mofetil Cooperative Study Group [see comments] Lancet 345 8961 1995 1321
148. K.P. Platz A.R. Mueller G. Blumhardt Nephrotoxicity following orthotopic liver transplantation: a comparison between cyclosporine and FK506 Transplantation 58 1994 170
149. K.P. Platz A.R. Mueller C. Willimski Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation Transplant Proc 30 1998 2232
150. K.P. Platz A.R. Mueller M. Zytowski Management of acute steroid-resistant rejection after liver transplantation World J Surg 20 1996 1052
151. R.J. Polson B. Portmann J. Neuberger Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis Gastroenterology 97 1989 715
152. M.K. Porayko S.C. Textor R.A.F. Krom Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation Mayo Clin Proc 69 1994 105
153. D. Portela R. Patel J.J. Larson-Keller OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation J Infect Dis 171 1995 1014
154. G.A. Porter W.M. Bennett S.G. Sheps Cyclosporine-associated hypertension Arch Intern Med 150 1990 280
155. R.S. Poston M. Billingham E.G. Hoyt Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model Circulation 100 1999 67
156. E. Prados V. Cuervas-Mons M. De La Mata Outcome of autoimmune hepatitis after liver transplantation Transplantation 66 1998 1645
157. J. Pratschke R. Neuhaus S.G. Tullius Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation Transplantation 64 1997 938
158. C.B. Ramirez M.I. Sebayel T. Kizilisik Early steroid withdrawal after liver transplantation Transplant Proc 30 1998 3182
159. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group [see comments] Lancet 344 8920 1994 423
160. V. Ratziu D. Samuel M. Sebagh Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease J Hepatol 30 1999 131
161. R. Reding P.E. Wallemacq M.E. Lamy Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children Transplantation 57 1994 93
162. B. Ringe F. Braun T. Lorf Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept Transplant Proc 30 1998 1415
163. M.A. Rodino N. Schachter E. Shane Endocrine and metabolic considerations of organ transplantation L.C. Ginns A.B. Cosimi P.J. Morris Transplantation 1999 Blackwell Science Malden, MA 672
164. H.R. Rosen C.R. Schackleton L. Higa Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation [see comments] Am J Gastroenterol 92 1997 1453
165. P.A. Rowe G.M. Rocker A.G. Morgan OKT3 and pulmonary capillary permeability Br Med J (Clin Res Ed) 295 6606 1987 1099
166. L. Sanchez-Urdazpal A.J. Czaja B. Van Hoek Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis Hepatology 15 1992 215
167. M. Sattler F.P. Guengerich C.H. Yun Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat Drug Metab Dispos 20 1992 753
168. M. Sebagh Q. Farges A. Kalil Sclerosing cholangitis following human orthotopic liver transplantation Am J Surg Pathol 19 1995 81
169. S.N. Sehgal Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 1998 335
170. R.A. Seifeldin K.R. Lawrence A.F. Rahamtulla Generalized seizures associated with the use of muromonab-CD3 in two patients after kidney transplantation Ann Pharmacother 31 1997 586
171. M.J. Semigran Cardiovascular considerations of organ transplantation L.C. Ginns A.B. Cosimi P.J. Morris Transplantation 1999 Blackwell Science Malden, MA 651
172. C. Sempoux Y. Horsmans J. Lerut Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation Liver 17 1997 311
173. C. Sgro Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review Toxicology 105 1995 23
174. L.S. Sher C.A. Cosenza J. Michel Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group Transplantation 64 1997 258
175. F.S. Shihab W.M. Bennett A.M. Tanner Mechanism of fibrosis in experimental tacrolimus nephrotoxicity Transplantation 64 1997 1829
176. T.M. Sievers S.J. Rossi R.M. Ghobrial Mycophenolate mofetil Pharmacotherapy 17 1997 1178
177. G.I. Slapak R. Saxena B. Portmann Graft and systemic disease in long-term survivors of liver transplantation Hepatology 25 1997 195
178. H.W. Sollinger Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group Transplantation 60 1995 225
179. H. Solomon T.A. Gonwa E. Mor OKT3 rescue for steroid-resistant rejection in adult liver transplantation Transplantation 55 1993 87
180. C. Spieker W. Zidek M. Barenbrock Cardiovascular side effects after renal allograft rejection therapy with Orthoclone: prevention with nitrendipine J Cardiovasc Pharmacol 1 18 Suppl 1991 S79
181. T.E. Starzl A.J. Demetris N. Murase Cell migration, chimerism, and graft acceptance [see comments] Lancet 339 8809 1992 1579
182. T.E. Starzl C.G. Groth L. Brettschneider Orthotopic homotransplantation of the human liver Ann Surg 168 1968 392
183. T.E. Starzl G.B. Klintmalm K.A. Porter Liver transplantation with use of cyclosporin a and prednisone N Engl J Med 305 1981 266
184. T.E. Starzl K.A. Porter V. Mazzaferro Hepatotrophic effects of FK506 in dogs Transplantation 51 1991 67
185. T.E. Starzl S. Todo J. Fung FK 506 for liver, kidney, and pancreas transplantation Lancet 2 8670 1989 1000
186. M.D. Stegall G. Everson G. Schroter Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity Transplantation 60 1995 1057
187. M.D. Stegall G.T. Everson G. Schroter Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss Hepatology 25 1997 173
188. M.D. Stegall M.E. Wachs G. Everson Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus Transplantation 64 1997 1755
189. S. Takaya O. Bronsther S. Todo Retransplantation of liver: a comparison of FK506- and cyclosporine-treated patients Transplant Proc 23 1991 3026
190. K. Tamura T. Fujimura T. Tsutsumi Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell Transplantation 59 1995 1606
191. J. Tchervenkov C. Flemming R.D. Guttmann Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation Transplant Proc 29 1997 13S
192. A. Tejani K.M. Butt M.R. Khawar Cyclosporine experience in renal transplantation in children Mt Sinai J Med 54 1987 467
193. The US Multicenter FK506 Liver Study Group A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation N Engl J Med 331 1994 1110
194. G.K. Thyagarajan A. Cobanoglu W. Johnston FK506-induced fulminant leukoencephalopathy after single-lung transplantation Ann Thorac Surg 64 1997 1461
195. M.J. Tocci D.A. Matkovich D.A. Collier The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes J Immunol 143 1989 718
196. H.V. Torocsik R.G. Curless J. Post FK506-induced leukoencephalopathy in children with organ transplants Neurology 52 1999 1497
197. D.J. Trepanier H. Gallant D.F. Legatt Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update Clin Biochem 31 1998 345
198. T.E. Trouillot R. Shrestha I. Kam Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis Liver Transplant Surg 5 1999 375
199. A.G. Tzakis J.J. Fung S. Todo Use of FK 506 in pediatric patients Transplant Proc 23 1991 924
200. J. Van de Stadt M. Gelin N. Bourgeois Liver transplantation for fulminant and subacute viral hepatic failure in adults Transplant Proc 22 1990 1505
201. B. van Hoek R.H. Wiesner J. Ludwig Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome Transplant Proc 23 1991 1442
202. J. Vanhaecke J. Van Cleemput J.V. Van Lierde Safety and efficacy of low dose simvastin in cardiac transplant recipients treated with cyclosporine Transplantation 58 1994 42
203. R. Venkataramanan A. Jain V.S. Warty Pharmacokinetics of FK 506 in transplant patients Transplant Proc 23 1991 2736
204. R. Venkataramanan A. Jain V.W. Warty Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine Transplant Proc 23 1991 931
205. M. Vilella-Bach P. Nuzzi Y. Fang The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression J Biol Chem 274 1999 4266
206. F. Vincenti M. Lantz J. Birnbaum A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation Transplantation 63 1997 33
207. T.A. Waldmann J. O'Shea The use of antibodies against the IL-2 receptor in transplantation Curr Opin Immunol 10 1998 507
208. W.J. Wall C.N. Ghent A. Roy Use of OKT3 monoclonal antibody as induction therapy for control of rejection in liver transplantation Dig Dis Sci 40 1995 52
209. W.J. Wall Use of antilymphocyte induction therapy in liver transplantation Liver Transpl Surg 54 suppl 1 1999 S64
210. C.J. Watson P.J. Friend N.V. Jamieson Sirolimus: a potent new immunosuppressant for liver transplantation Transplantation 67 1999 505
211. R.H. Weisner P. Martin R. Stribling Post-transplant care/medical complications D.J. Norman W.N. Suki Primer on Transplantation 1998 American Society of Transplant Physicians Thorofare, NJ 343
212. P.F. Whitington J.C. Emond S.H. Whitington Small-bowel length and the dose of cyclosporine in children after liver transplantation N Engl J Med 322 1990 733
213. G. Wiederrecht E. Lam S. Hung The mechanism of action of FK-506 and cyclosporin A Ann NY Acad Sci 696 1993 9
214. R.H. Wiesner A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group Transplantation 66 1998 493
215. M.I. Wilde K.L. Goa Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection Drugs 51 1996 865
216. P.Y.N. Wong B. Portmann J.G. O'Grady Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression J Hepatol 17 1993 284
217. E.S. Woodle D.S. Bruce M. Josephson FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation Clin Transplant 10 1996 323
218. H.L. Wright C.F. Bou-Abboud T. Hassanein Disease recurrence and rejection following transplantation for autoimmune chronic active liver disease Transplantation 53 1992 136
219. R. Yatscoff D. LeGatt R. Keenan Blood distribution of rapamycin Transplantation 56 1993 1202
220. J.J. Zimmerman G.M. Ferron H.K. Lim The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin) J Clin Pharmacol 39 1999 1155